P/E ratio for Sino Biopharmaceutical (1177.HK)
P/E ratio as of April 2024 (TTM): 14.4
According to Sino Biopharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.3695. At the end of 2019 the company had a P/E ratio of 43.9.
P/E ratio history for Sino Biopharmaceutical from 2011 to 2020
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2019 | 43.9 | 616.94% |
| 2018 | 6.13 | -84.93% |
| 2017 | 40.6 | 91.67% |
| 2016 | 21.2 | -25.77% |
| 2015 | 28.6 | 24.89% |
| 2014 | 22.9 | -22.86% |
| 2013 | 29.7 | 43.53% |
| 2012 | 20.7 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.